Marlyn Mayo, MD: Improving Pruritus Management in PBC Care
Mayo explains current shortcomings of pruritus care in PBC and what the additions of elafibranor, seladelpar, and other agents in development may offer.
Jörn Schattenberg, MD: Preventing MASH Cirrhosis Progression with Pegozafermin
Schattenberg reviews results from a posthoc analysis of the ENLIVEN study suggesting pegozafermin’s impact on preventing progression to cirrhosis.
Jörn Schattenberg, MD: Pegozafermin and Preventing Progression to Cirrhosis in MASH
Schattenberg explains pegozafermin’s mechanism of action and describes the importance of preventing progression to cirrhotic MASH.
Clinical Quiz: AASLD Guidelines for Noninvasive Testing in Chronic Liver Disease
Test your knowledge of the 2024 AASLD Practice Guidelines on blood- and imaging-based noninvasive liver disease assessment with this clinical quiz!
Clinical Quiz: Impact of New MASLD Nomenclature on 2023 AASLD NAFLD Guidance
Test your knowledge of the AASLD NAFLD Practice Guidance and its clinical application in light of the new MASLD nomenclature.
Malin Fromme, MD: Lung, Liver Risk Stratification in Alpha-1 Antitrypsin Deficiency
Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.
Pavel Strnad, MD: The Underlying Molecular Mechanisms of PI*ZZ AATD Liver Disease
Strnad reviews findings from a proteomic analysis about AATD-associated liver disease and how they may aid future disease monitoring and drug development.
Gideon Hirshfield, FRCP, PhD: Developing Therapies to Address Pruritus in PBC
Hirschfield describes the need for therapies that address itch in PBC and explains what linerixibat, an IBAT inhibitor, may offer for pruritus.
Country-Level Socioeconomic Status, Healthcare Impact AKI Outcomes in Cirrhosis
Kavish Patidar, DO, explains how socioeconomic status and healthcare delivery impact outcomes in patients with acute kidney injury and cirrhosis.
Marcelo Kugelmas, MD: Elafibranor (Iqirvo) Does Not Impact Renal Function in PBC
Kugelmas reviews findings from a secondary analysis of the phase 3 ELATIVE trial suggesting elafibranor is associated with stable kidney function.
Eric Lawitz, MD: FXR Agonists for MASH, What FXR314 May Offer for Safety, Efficacy
Lawitz explains issues with traditional FXR agonists for MASH treatment and how FXR314 differs, potentially offering a more safe and efficacious option.
Rohit Loomba, MD: Promising Phase 2a HERALD Data for ALG-055009 in MASH
Loomba reviews safety and efficacy data for the thyroid hormone receptor beta agonist from a phase 2a trial presented at AASLD The Liver Meeting 2024.
A. Sidney Barritt, MD: Real-World Data Suggest Benefit of GLP-1 RAs for MASLD
Barritt reviews real-world data about the use and benefits of GLP-1 RAs in patients with MASLD.
Kris Kowdley, MD: Elafibranor Remains Safe, Efficacious for PBC Through 3 Years
Kowdley reviews open-label extension data for biochemical response, ALP normalization, and pruritus improvement from the phase 3 ELATIVE study.
Elafibranor Shows Sustained Efficacy for PBC, Improves Pruritus and Fatigue
Findings from the open-label extension of the ELATIVE study suggest sustained safety and efficacy for up to 3 years, with improvements in itch and sleep.
Diabetes Linked to Worse Transplant-Free Survival in Primary Biliary Cholangitis
Diabetes was associated with an increased risk of liver transplant or death and with liver-specific events in patients with PBC.
Wei Zhang, MD, PhD: Naltrexone’s GI, Liver Safety for Alcohol Use Disorder Treatment
Zhang explains the safety of different FDA-approved alcohol use disorder drugs in patients with alcohol-associated liver disease.
Weekend Admission for Acute Liver Failure Linked to Higher Post-Transplant Mortality
Liver transplant waitlisting after a weekend was associated with higher 1-year post-transplant mortality compared with patients listed on a weekday.
Jeffrey Teckman, MD: Predicting Severe Liver Disease Risk in ZZ, SZ AATD
Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.
GLP-1RAs Reduce Risk of Hepatic Decompensation in Alcohol-Associated Liver Disease
GLP-1RA use was associated with a reduced risk of adverse liver outcomes in patients with alcohol-associated liver disease and type 2 diabetes.
Study Highlights Racial, Ethnic Disparities in Liver Transplant Waitlisting, Allocation
Compared with non-Hispanic White patients, racial/ethnic minority patients were more likely to be removed from the waitlist and not receive a transplant.
Mediterranean Diet May Help Reduce Risk of Adverse Liver-Related Outcomes in MASLD
High adherence to the Mediterranean diet was linked to a lower risk of liver-related outcomes as measured by the Liver Risk score.
ITCH-E: Pruritus Linked to Worse Health-Related Quality of Life in PBC
Patients with PBC and moderate/severe pruritus face a greater health-related quality of life burden and impaired activity than those with no/mild itch.
Kris Kowdley, MD: Elafibranor Improves Long-Term Transplant-Free Survival in PBC
Kowdley explains how treatment with elafibranor (Iqirvo) improves transplant-free survival based on changes in GLOBE and UK-PBC prognostic scores.
Minjee Kim, MD: Understanding Sleep’s Impact on Post-Liver Transplant Outcomes
Kim explains how poor sleep is linked to negative impacts on mental health, physical health, and frailty after liver transplantation.
Elafibranor Improves Predicted Transplant-Free Survival Based on GLOBE, UK-PBC Scores
Treatment with elafibranor (Iqirvo) improved prognostic GLOBE and UK-PBC scores as early as week 4 in the phase 3 ELATIVE trial.
Chari Cohen, DrPH, MPH: Healthcare Providers’ Role in HBV Clinical Trial Diversity
Cohen explains patient perspectives about how healthcare providers can help address the lack of diversity in chronic HBV clinical trials.
Vitamin D Deficiency Linked to Worse Autoimmune Hepatitis Outcomes
Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.
Jonathan Stine, MD: Exercise’s Benefit in MASH is Independent of Weight Loss
Stine reviews findings from a posthoc analysis of the NASHFit trial suggesting the impact of exercise on MASH resolution, even without weight loss.
Telehealth Could Address HCV Care Barriers, Expand Treatment for People Who Inject Drugs
Zoi Papalamprakopoulou, MD, explains telehealth’s potential to aid HCV treatment in high-risk populations and how patients perceive this care modality.
